Matthias Will
Chief Development Officer Autolus
Matthias Will serves as Autolus’ Chief Development Officer. Previously, he served as Chief Medical Officer at Dren Bio, Inc., where he led the expansion of the clinical team and oversaw the submission of two INDs for hematologic cancer candidates. Prior to that, he was Vice President of Clinical Development at CRISPR Therapeutics, leading allogeneic CAR T programs targeting CD70 and an early-stage CD70-NK program. He also led clinical development at CytomX Therapeutics and held senior roles at Gilead Sciences and Novartis Oncology. Dr. Will earned his M.D. from Hannover Medical School and trained in hematology and oncology at the University of Tübingen.
